$30.76 Million in Sales Expected for Insmed Incorporated (NASDAQ:INSM) This Quarter

Wall Street analysts expect that Insmed Incorporated (NASDAQ:INSM) will announce sales of $30.76 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Insmed’s earnings, with the lowest sales estimate coming in at $27.80 million and the highest estimate coming in at $33.00 million. The company is expected to announce its next quarterly earnings results on Tuesday, October 29th.

According to Zacks, analysts expect that Insmed will report full-year sales of $114.09 million for the current financial year, with estimates ranging from $104.40 million to $120.92 million. For the next year, analysts anticipate that the business will report sales of $180.69 million, with estimates ranging from $162.12 million to $219.36 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Insmed.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. The firm had revenue of $30.00 million for the quarter, compared to analyst estimates of $26.30 million.

A number of research firms have commented on INSM. ValuEngine cut Insmed from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 17th. BidaskClub cut Insmed from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 17th. Finally, Zacks Investment Research upgraded Insmed from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research note on Wednesday, July 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. Insmed presently has a consensus rating of “Buy” and a consensus price target of $36.63.

NASDAQ:INSM traded down $0.90 during trading hours on Tuesday, reaching $16.23. 1,100,999 shares of the stock were exchanged, compared to its average volume of 1,484,426. The company has a debt-to-equity ratio of 1.01, a current ratio of 7.54 and a quick ratio of 7.31. The stock has a 50-day simple moving average of $22.63. Insmed has a twelve month low of $11.31 and a twelve month high of $33.13. The stock has a market cap of $1.53 billion, a P/E ratio of -3.89 and a beta of 2.78.

In other news, insider Orlov S. Nicole Schaeffer sold 12,000 shares of the company’s stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $23.24, for a total transaction of $278,880.00. Following the sale, the insider now owns 36,350 shares of the company’s stock, valued at $844,774. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO William Lewis sold 400,000 shares of the company’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $26.00, for a total value of $10,400,000.00. Following the sale, the chief executive officer now directly owns 480,672 shares in the company, valued at approximately $12,497,472. The disclosure for this sale can be found here. 4.95% of the stock is currently owned by corporate insiders.

A number of large investors have recently bought and sold shares of the stock. FMR LLC increased its holdings in Insmed by 0.6% in the first quarter. FMR LLC now owns 11,630,784 shares of the biopharmaceutical company’s stock valued at $338,107,000 after buying an additional 67,250 shares during the last quarter. Eagle Asset Management Inc. purchased a new position in Insmed in the second quarter valued at $38,439,000. Vivo Capital LLC purchased a new position in Insmed in the first quarter valued at $34,020,000. Carillon Tower Advisers Inc. purchased a new position in Insmed in the second quarter valued at $26,785,000. Finally, Emerald Advisers LLC increased its holdings in Insmed by 52.8% in the first quarter. Emerald Advisers LLC now owns 921,527 shares of the biopharmaceutical company’s stock valued at $26,789,000 after buying an additional 318,482 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

See Also: Strike Price

Get a free copy of the Zacks research report on Insmed (INSM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.